TL;DR
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for diabetes and obesity, significantly increase the risk of residual gastric content (RGC) during endoscopic procedures, even with standard bowel preparation. This finding is particularly concerning for patients undergoing concurrent colonoscopies, highlighting the need for more stringent preoperative management strategies.
What Problem Does This Paper Address?
GLP-1 RAs have become increasingly popular for managing type 2 diabetes and obesity due to their effectiveness in glycemic control and weight loss. However, a known side effect is delayed gastric emptying, which can lead to increased residual gastric content (RGC) in the stomach. This RGC poses a risk during procedures like esophagogastroduodenoscopy (EGD) and colonoscopy, potentially leading to aspiration or the need to cancel or repeat the procedure. While previous studies have examined RGC in the context of EGD, there's a lack of specific analysis on patients undergoing concurrent colonoscopy, where bowel preparation is also a factor. This paper aims to clarify the impact of GLP-1 RAs on RGC in both EGD alone and EGD with concurrent colonoscopy, especially considering the standard bowel preparation protocols.
Methods
This study employed a retrospective case-control design. Researchers analyzed data from Shanghai East Hospital between January 2023 and June 2025. They identified "cases" as patients with endoscopically confirmed increased RGC and "controls" as patients without RGC, matched at a 1:2 ratio for age and sex. The primary analysis involved multivariable logistic regression to determine the independent association between GLP-1 RA use and increased RGC, while accounting for potential confounding factors. Data on patient demographics, medical conditions, and procedural details were extracted from electronic health records.
Datasets
The study utilized data from the internal endoscopy database of Shanghai East Hospital, encompassing 131,255 procedures performed between January 2023 and June 2025. The final analysis included 3746 patients (1257 with increased RGC and 2489 controls).
Key Insights and Ideas
- GLP-1 RAs are a potent driver of RGC: The study strongly suggests that GLP-1 RAs are a significant independent risk factor for increased residual gastric content, even when other factors are controlled for.
- Concurrent colonoscopy doesn't negate the risk: Standard bowel preparation for colonoscopy, which is designed to clear the lower GI tract, does not seem to sufficiently mitigate the gastric-emptying delay caused by GLP-1 RAs. This implies that the issue is primarily in the upper GI tract.
- Diabetes complications exacerbate the problem: Patients with diabetes complications showed a significantly higher likelihood of increased RGC, suggesting that underlying neuropathy or other diabetes-related issues might worsen the effect of GLP-1 RAs on gastric motility.
- Aborted procedures are a real consequence: The study found a substantially higher rate of procedure cancellations among patients with increased RGC, underscoring the clinical impact of this finding.
- Current guidelines might be too liberal: The findings challenge the more relaxed approach recommended by some societies (like the AGA) for patients on GLP-1 RAs who are asymptomatic, suggesting a need for more stringent preoperative assessment.
Key Results
- Among 131,255 screened procedures, 3746 patients were included in the analysis.
- GLP-1 RA users had significantly higher odds of increased RGC:
- Unadjusted OR: 15.20 (95% CI 5.98–38.61)
- Adjusted OR (aOR): 13.31 (95% CI 5.07–34.93)
- Diabetes-related complications were also a significant risk factor for RGC (aOR = 8.89, 95% CI 3.15–25.12).
- In the subgroup of GLP-1 RA users undergoing concurrent colonoscopy (n=22), a striking 86.4% (19 out of 22) exhibited increased RGC. All of these patients also had solid stool during colonoscopy, indicating that the RGC was present despite bowel preparation.
- Procedures were aborted in 10.02% of patients with increased RGC, compared to 3.87% overall.
- No aspiration events were reported in the study.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-center retrospective study: This limits generalizability and introduces potential biases.
- Relatively small GLP-1 RA cohort: The sample size for GLP-1 RA users was modest, impacting the precision of effect estimates and the ability to conduct more detailed subgroup analyses. A multicenter study is recommended.
- Electronic medical record data: Reliance on EMRs for medication data might miss prescriptions from external healthcare systems, and the objective measurement of RGC was visual estimation rather than precise gastric volume ultrasound.
- Potential confounding from other medications: The influence of other medications that affect gastrointestinal motility (e.g., opioids) could not be fully controlled.
Future work should focus on multicenter studies to confirm these findings with larger cohorts. Investigating more objective methods for assessing gastric emptying, such as gastric ultrasound, pre-procedure would be beneficial. The authors also suggest exploring individualized preoperative plans, potentially involving longer fasting periods or the use of prokinetic agents, for high-risk patients.
Summary updated